LFM A12

Known as: LFM-A12 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2017
02420022017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The frequency of breathing and peak flow rate of exhaled air are necessary parameters to detect chronic obstructive pulmonary… (More)
Is this relevant?
2017
2017
The goals of the present study were to define the anticancer activity of LFM-A13 (α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
OBJECTIVE To investigate the role of non-receptor tyrosine kinase Tec in the production of TNF-α and IL-1β from macrophages… (More)
Is this relevant?
2011
2011
The present study documents the chemosensitizing anti-leukemic activity of the leflunomide metabolite (LFM) analog, LFM-A13, a… (More)
Is this relevant?
2007
2007
The leflunomide (CAS 75706-12-6) metabolite (LFM) analog alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)-propenamide… (More)
Is this relevant?
2007
2007
Molecular modeling studies led to the identification of LFM-A13 (alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl… (More)
Is this relevant?
2004
2004
The purpose of the present study was to evaluate the effectiveness of targeting Bruton's tyrosine kinase (BTK) with a specific… (More)
  • figure 1
Is this relevant?
2004
2004
The specific inhibitor of the protein tyrosine kinase, Bruton's tyrosine kinase (BTK), alpha-cyano-beta-hydroxy-beta-methyl-N-(2… (More)
Is this relevant?
2003
2003
The leflunomide metabolite analog alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)-propenamide (LFM-A13) is a… (More)
Is this relevant?
2002
2002
The purpose of the present study was to examine the in vivo pharmacokinetics and activity of alpha-cyano-beta-hydroxy-beta-methyl… (More)
Is this relevant?